

SELECTIVE H₃ RECEPTOR ISOFORMS ACTIVATE AKT/GSK AXIS AND ERK IN RAT CORTICAL NEURONS

Chiara Mariottini¹, Gerold Bongers³, Rob Leurs³, Silvia Fossati², Alberto Chiarugi², Patrizio Blandina² and M. Beatrice Passani²

¹Dipartimento di Fisiologia, V.le Morgagni 65, Firenze, Italy

²Dipartimento di Farmacologia Preclinica e Clinica, V.le Pieraccini 6, Firenze, Italy

³Department of Medicinal Chemistry, Vrije Universiteit, Amsterdam, The Netherlands

The H₃ receptor (H₃R) shows functional constitutive activity, polymorphisms in humans and rodents with a differential distribution of splice variants in the CNS, and potential coupling to different intracellular signal transduction mechanisms, such as inhibition of adenylate cyclase [1], MAPK phosphorylation [2]. Using RT-PCR we show that ED17 cortical neurons maintained in culture for 4, 7 or 11 days stably express H₃R mRNA; furthermore cortical neurons express two out of the three functional H₃R isoforms, namely A and C. Consistent with previously published data [2], the primers used recognise isoforms A, B and C in adult brains.

Incubation of cortical neurons with histamine (HA, 100 nM), the H₃R agonists R- α -methylhistamine (RAMH, 100 nM) or imzepip (10 nM) induce a time dependent activation of the Akt/GSK3 β axis that peaks at 60 min. Activation of Akt/GSK3 β axis is inhibited by the H₃R antagonist thioperamide (10 μ M) and by LY294002 (50 μ M) an inhibitor of PI3 kinase. We also demonstrate that the H₃R agonist imzepip (10 nM) induces phosphorylation of ERK 1, 2 that reaches a maximum at 15 min. ERK activation was inhibited by the MEK inhibitor UO126 (10 μ M) and the H₃R antagonist thioperamide.

H₃R ligands affect cognition, the sleep-wake cycle, obesity and epilepsy, which are physiological and pathological conditions that are the main focus of research into the therapeutic potential of selective H₃R ligands. Given the molecular and pharmacological heterogeneity of the H₃R, it is important to understand if and which transduction cascades are associated to different H₃R isoforms in light of more selective therapeutic treatments devoid of unwanted side effects.

1 Lovenberg TW., Roland BL., Wilson SJ., Jiang X., Pyati J., Huvar A., Jackson MR., Erlander MG. (1999) *Mol Pharmacol* 55(6):1101-7.

2 Drutel G., Peitsaro N., Karlstedt K., Wieland K., Smit MJ., Timmerman H., Panula P., Leurs R. (2001) *Mol Pharmacol* 59(1):1-8.